Lajos Pusztai
Yale University · Yale University: Professor of Medicine, Section of Medical Oncology · SWOG Cancer Research Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lajos Pusztai as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:08 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04567420 · DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Criterium, Inc. · active not recruiting · Breast Cancer · principal investigator
- Ph1/Ph2NCT02988648 · A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I SymporterYale University · withdrawn · Breast Cancer · principal investigator
- Ph3NCT02954874 · Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNational Cancer Institute (NCI) · active not recruiting · Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7 · principal investigator
- Ph1/Ph2NCT02489448 · Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast CancerYale University · completed · Breast Neoplasms · principal investigator
- Ph2NCT02236572 · Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk ScoreYale University · terminated · Breast Cancer · principal investigator
- Ph2NCT01855828 · Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast CancerYale University · completed · Her2-Positive Breast Cancer · principal investigator
- N/ANCT01855503 · Breast Cancer Molecular Analysis ProtocolYale University · completed · Metastatic Breast Cancer · principal investigator
- N/ANCT01159236 · Molecular Triaging of Newly Diagnosed Breast CancerM.D. Anderson Cancer Center · withdrawn · Breast Cancer · study chair
- Ph3NCT00336791 · Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast CancerM.D. Anderson Cancer Center · completed · Breast Cancer · principal investigator
- Ph3NCT00103233 · Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast CancerSWOG Cancer Research Network · completed · Breast Cancer · unknown
- Ph1/Ph2NCT00037609 · Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer PatientsM.D. Anderson Cancer Center · completed · Breast Neoplasms, Metastases, Neoplasm · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Genomics, Genetics and Epigenetics Research ProgramP30CA016359 · NCI · YALE UNIVERSITY · fiscal years 2024 to 2026 · $69,206 awarded in 2026Same name and institution; not confirmed by an ID
- Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcomeR01CA219647 · NCI · YALE UNIVERSITY · fiscal years 2017 to 2020 · $474,931 awarded in 2020Same name and institution; not confirmed by an ID
- Preoperative chemotherapy for breast cancerR01CA106290 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2005 to 2007 · $184,697 awarded in 2007Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT02954874
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:08 UTC. The ranking covers the 200 most relevant of 85 PubMed records, and a shared surname and initials can bring in a namesake. All 85 on PubMed
- Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med · 20202,673 citationsRCR 117.0
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.J Clin Oncol · 20161,253 citationsRCR 38.8
- 1,071 citationsRCR 71.6
- 1,059 citationsRCR 26.5
- Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.Nat Med · 2014901 citationsRCR 22.3
- 897 citationsRCR 19.2
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med · 2021778 citationsRCR 43.5
- 620 citationsRCR 24.3
- Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.N Engl J Med · 2024520 citationsRCR 60.7
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.N Engl J Med · 2016456 citationsRCR 12.7